Biokuris
We care about patients.
BiOkuris has developed the next generation of medical nutrition products tailored to the unmet medical needs of patients with chronic intestinal diseases such as IBD, IBS and Candidiasis.
We believe that patients deserve specific, safe, effective, and science-driven treatments that reduce their daily burden and help them to restore balance.
Our solutions have been specifically designed to improve both the physiopathology and quality of life for the millions of patients living with chronic intestinal diseases.
Our innovative platform
We target unmet medical needs in gut health.
Inflammatory Bowel Diseases (IBD)
40% of Crohn’s disease and ulcerative colitis patients with long-standing remission continue to experience IBS-like symptoms.Such ‘IBS-like symptoms’ in IBD patients need to be both comprehensively and specifically targeted to fully satisfy patients’ expectations and radically improve their quality of life.
Irritable Bowel Syndrome (IBS)
Affects 10-20% of the populationBiOkuris is committed to providing targeted, clinically-proven solutions for IBS patients, ensuring a complete and multifactorial effect on their physiopathology, thereby improving their quality of life.
Candidiasis
Occurring in 75% of women at least once in their livesAs the gut is the source of Candida albicans, targeting this commensal in the gut itself could reduce, even prevent, fungal infections in millions of people each year.
Inflammatory Bowel Diseases (IBD)
Back to home
40% of Crohn’s disease and ulcerative colitis patients with long-standing remission continue to experience IBS (Irritable Bowel Syndrome)-like symptoms.
Even during and after treatment involving biosimilars and a full control of inflammation, 40% of patients still suffer from abdominal pain, bloating, constipation, or diarrhea.
The etiology of IBS/IBS-like symptoms is multifactorial, combining hypersensitivity of the digestive tract, low-grade local inflammation, and changes in the intestinal flora with dysbiosis, increased intestinal permeability and bile acid malabsorption.
Existing and available drugs are only modestly effective, often developed to improve transit disorders and/or stool consistency via non-irritating laxatives for constipation, transit retarders for diarrhea, antispasmodics for bloating and anxiolytics.
Such ‘IBS-like symptoms’ in IBD patients need to be both comprehensively and specifically targeted to fully satisfy patients’ expectations and radically improve their quality of life.
Irritable Bowel Syndrome (IBS)
Back to home
IBS is a public health problem that affects 10-20% of the population, predominantly affecting women in Europe and North America. With a peak level of frequency between the ages of 20 and 40, it causes young individuals to experience significantly disabling symptoms, resulting in a considerable reduction in their quality of life.
The physiopathology is complex and multifactorial, with existing treatments in Europe only providing a temporary relief of symptoms, without truly addressing the underlying causes. The margin of therapeutical gains when trialed together with placebos rarely exceeds 10%.
BiOkuris is committed to providing targeted, clinically-proven solutions for IBS patients, ensuring a complete and multifactorial effect on their physiopathology, thereby improving their quality of life.
Candidiasis
Back to home
Candida albicans is a type of yeast that can colonize any segment of the digestive tract or vagina. Its deleterious effects are well documented, ranging locally from potentially IBD-caused colitis to cutaneous-mucosal candidiasis, with vaginal candidiasis occurring in 75% of women at least once in their lives, and systemic infections that often occur in hospital, incurring significant medical and financial cost.
As the gut is the source of Candida albicans, targeting this commensal in the gut itself could reduce, even prevent, fungal infections in millions of people each year.
Our innovative platform
Two patented ingredients, with multiple action mechanisms
BiOkuris is made using two proprietary active ingredients that are derived from nature, vegan, safe, and non-GMO, both manufactured in Belgium.
We have already yielded exceptional results via multiple in-vitro, in-vivo, and human clinical trials that have confirmed its positive effect on:
- Intestinal hypersensitivity
- Inflammation
- Leaky gut syndrome
- Gut microbiota homeostasis
- Chelation of bile acids and various xenobiotics
Three products at a clinical stage
The company is now working on developing targeted solutions based on our proprietary ingredients and selected complementary technologies for each of the three identified unmet medical needs: IBD’s with IBS-like symptoms, IBS, and Candidiasis.
The products are being developed as medical foods and food supplements, allowing patients to play an active role in their treatment and take back control of their balance.
For more information or to enquire about co-development and commercial opportunities, please get in touch.
About us
Our company is located near Liege, in Belgium, and we benefit from the rich ecosystem of the “biotech-pharma valley” in Wallonia, allowing us to get access to the best resources to develop our projects. Most importantly, BiOkuris is part of the KitoZyme Group, who for the last 20 years has specialized in the design and manufacturing of biopolymers for Health & Nutrition, Agriculture and Personal Care.
KitoZyme is a global leader of natural ingredients derived from fungi, and has obtained multiple market authorizations and certifications, including GRAS, Novel Food, Medical Devices.
The company has built a strong scientific background and IP portfolio to support its applications in the markets that it serves.
In particular, since 2008, KitoZyme has developed a strong knowledge in Gastro-Intestinal Health, and based on breakthrough results obtained in 2017-2020, we decided to create a dedicated company, BiOkuris, to continue and strengthen the developments in this field.
BiOkuris is thus a start-up, but with a solid background !
Team
BiOkuris is led by a team combining expertise in Consumer Health, Biotechnology and Medicine.
